Abstract
Background: The prognosis and management of chronic liver diseases greatly depend on the amount and progression of liver fibrosis with the risk of developing cirrhosis. Liver biopsy, traditionally considered as the reference standard for the staging of fibrosis, has been challenged over the past decade by the development of novel noninvasive methodologies. Key Messages: Noninvasive methods rely on two different but complementary approaches: a ‘biological' approach based on the dosage serum biomarkers, and a ‘physical' approach based on the measurement of liver stiffness using transient elastography (TE). There are two clinically relevant endpoints for the staging of liver fibrosis: (1) significant fibrosis (indication for antiviral treatment in viral hepatitis B and C), and (2) cirrhosis (indication for screening of esophageal varices and hepatocellular carcinoma). TE (FibroScan®), FibroTest® and APRI have been the most extensively studied and validated methods, mainly in chronic hepatitis C. Combining two unrelated methods, such as TE and biomarkers, is an attractive approach that increases diagnostic performance and limits the drawback of both methodologies. TE appears to be an excellent tool for the early detection of cirrhosis with likely prognostic value in this setting. Thus far, however, it cannot replace upper endoscopy for screening of esophageal varices. The main limitation of TE in clinical practice is the impossibility of obtaining reliable liver stiffness measurements in around 20% of cases, mainly comprising obese patients. Conclusion: An increasing number of reliable noninvasive methods are now available that are widely used in clinical practice, mostly in viral hepatitis, resulting in a significant decrease in the need for liver biopsy.
References
1.
Castera L, Pinzani M: Non-invasive assessment of liver fibrosis: are we ready? Lancet 2010;375:1419-1420.
2.
Castera L: Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012;142:1293-1302.
3.
Imbert-Bismut F, Ratziu V, Pieroni L, et al: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075.
4.
Forns X, Ampurdanes S, Llovet JM, et al: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-992.
5.
Wai CT, Greenson JK, Fontana RJ, et al: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.
6.
Patel K, Gordon SC, Jacobson I, et al: Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-942.
7.
Leroy V, Monier F, Bottari S, et al: Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004;99:271-279.
8.
Rosenberg WM, Voelker M, Thiel R, et al: Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-1713.
9.
Sud A, Hui JM, Farrell GC, et al: Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004;39:1239-1247.
10.
Adams LA, Bulsara M, Rossi E, et al: Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-1873.
11.
Cales P, Oberti F, Michalak S, et al: A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-1381.
12.
Lok AS, Ghany MG, Goodman ZD, et al: Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005;42:282-292.
13.
Islam S, Antonsson L, Westin J, et al: Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005;40:867-872.
14.
Hui AY, Chan HL, Wong VW, et al: Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005;100:616-623.
15.
Zeng MD, Lu LG, Mao YM, et al: Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005;42:1437-1445.
16.
Fontana RJ, Kleiner DE, Bilonick R, et al: Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 2006;44:925-935.
17.
Koda M, Matunaga Y, Kawakami M, et al: FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007;45:297-306.
18.
Vallet-Pichard A, Mallet V, Nalpas B, et al: FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection: comparison with liver biopsy and FibroTest. Hepatology 2007;46:32-36.
19.
Angulo P, Hui JM, Marchesini G, et al: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854.
20.
Harrison SA, Oliver D, Arnold HL, et al: Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-1447.
21.
Fontana RJ, Goodman ZD, Dienstag JL, et al: Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789-798.
22.
Sandrin L, Fourquet B, Hasquenoph JM, et al: Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713.
23.
Roulot D, Czernichow S, Le Clesiau H, et al: Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008;48:606-613.
24.
Castera L, Forns X, Alberti A: Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008;48:835-847.
25.
Fraquelli M, Rigamonti C, Casazza G, et al: Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-973.
26.
Castera L, Foucher J, Bernard PH, et al: Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010;51:828-835.
27.
Myers RP, Pomier-Layrargues G, Kirsch R, et al: Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012;55:199-208.
28.
Castera L, Pinzani M: Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 2010;59:861-866.
29.
Mederacke I, Wursthorn K, Kirschner J, et al: Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int 2009;29:1500-1506.
30.
Arena U, Platon ML, Stasi C, et al: Liver stiffness is influenced by a standardized meal in patients with chronic HCV hepatitis at different stages of fibrotic evolution. Hepatology 2013;58:65-72.
31.
Berzigotti A, De Gottardi A, Vukotic R, et al: Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One 2013;8:e58742.
32.
Berzigotti A, Castera L: Update on ultrasound imaging of liver fibrosis. J Hepatol 2013;58:180-182.
33.
Poynard T, Morra R, Halfon P, et al: Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7:40.
34.
Lin ZH, Xin YN, Dong QJ, et al: Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726-736.
35.
Degos F, Perez P, Roche B, et al: Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010;53:1013-1021.
36.
Castera L, Vilgrain V, Angulo P: Non-invasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:666-675.
37.
Castera L, Vergniol J, Foucher J, et al: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
38.
Ziol M, Handra-Luca A, Kettaneh A, et al: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
39.
Corpechot C, El Naggar A, Poujol-Robert A, et al: Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006;43:1118-1124.
40.
Ganne-Carrie N, Ziol M, de Ledinghen V, et al: Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006;44:1511-1517.
41.
Foucher J, Chanteloup E, Vergniol J, et al: Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:403-408.
42.
Coco B, Oliveri F, Maina AM, et al: Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007;14:360-369.
43.
Arena U, Vizzutti F, Abraldes JG, et al: Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008;57:1288-1293.
44.
Yoneda M, Yoneda M, Mawatari H, et al: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008;40:371-378.
45.
Nobili V, Vizzutti F, Arena U, et al: Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008;48:442-448.
46.
Nahon P, Kettaneh A, Tengher-Barna I, et al: Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008;49:1062-1068.
47.
Nguyen-Khac E, Chatelain D, Tramier B, et al: Assessment of asymptomatic liver fibrosis in alcoholic patients using Fibroscan: prospective comparison with 7 non-invasive laboratory tests. Aliment Pharmacol Ther 2008:1188-1198.
48.
Marcellin P, Ziol M, Bedossa P, et al: Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009;29:242-247.
49.
Chan HL, Wong GL, Choi PC, et al: Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009;16:36-44.
50.
Wong VW, Vergniol J, Wong GL, et al: Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-462.
51.
Zarski JP, Sturm N, Guechot J, et al: Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012;56:55-62.
52.
Shaheen AA, Wan AF, Myers RP: FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007;102:2589-2600.
53.
Talwalkar JA, Kurtz DM, Schoenleber SJ, et al: Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007;5:1214-1220.
54.
Friedrich-Rust M, Ong MF, Martens S, et al: Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960-974.
55.
Tsochatzis EA, Gurusamy KS, Ntaoula S, et al: Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011;54:650-659.
56.
Friedrich-Rust M, Nierhoff J, Lupsor M, et al: Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 2012;19:e212-e219.
57.
Huwart L, Sempoux C, Vicaut E, et al: Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008;135:32-40.
58.
Ferraioli G, Tinelli C, Dal Bello B, et al: Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 2012;56:2125-2133.
59.
Sebastiani G, Vario A, Guido M, et al: Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006;44:686-693.
60.
Sebastiani G, Halfon P, Castera L, et al: SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009;49:1821-1827.
61.
Poynard T, Ingiliz P, Elkrief L, et al: Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One 2008;3:e3857.
62.
Boursier J, de Ledinghen V, Zarski JP, et al: A new combination of blood test and Fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011;106:1255-1263.
63.
Castera L, Sebastiani G, Le Bail B, et al: Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010;52:191-198.
64.
Boursier J, de Ledinghen V, Zarski JP, et al: Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology 2012;55:58-67.
65.
Castera L, Le Bail B, Roudot-Thoraval F, et al: Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol 2009;50:59-68.
66.
Carrion JA, Navasa M, Bosch J, et al: Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006;12:1791-1798.
67.
Vizzutti F, Arena U, Romanelli RG, et al: Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45:1290-1297.
68.
Castera L, Pinzani M, Bosch J: Non invasive evaluation of portal hypertension using transient elastography. J Hepatol 2012;56:696-703.
69.
Vergniol J, Foucher J, Terrebonne E, et al: Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011;140:1970-1979.
70.
Robic MA, Procopet B, Metivier S, et al: Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011;55:1017-1024.
71.
Ngo Y, Munteanu M, Messous D, et al: A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006;52:1887-1896.
72.
Naveau S, Gaude G, Asnacios A, et al: Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009;49:97-105.
73.
Parkes J, Roderick P, Harris S, et al: Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010;59:1245-1251.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
